Jasper Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Jasper Therapeutics

06/03/2024 12:00

* Jasper Therapeutics Inc  JSPR.OQ  reported a quarterly
adjusted
loss of $1.50​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-3.60.  The mean expectation of four analysts
for the quarter was for a loss of $1.61 per share. Wall Street
expected results to range from $-1.70 to $-1.50 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Jasper Therapeutics Inc's reported EPS for the quarter was
a
loss of $1.50​.
    * The company reported a quarterly loss of $16.58 million.
    * Jasper Therapeutics Inc shares had risen by 215.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is  "buy."

Wall Street's median 12-month price target for Jasper
Therapeutics Inc is $67.50 
This summary was machine generated from LSEG data March 6 at
12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.61          -1.50          Beat
 Sep. 30 2023      -1.55          -1.60          Missed
 Jun. 30 2023      -1.50          -1.50          Met
 Mar. 31 2023      -1.62          -1.60          Beat